tri-O-acetyl-5-deoxy-D-ribofuranose | 202119-71-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tri-O-acetyl-5-deoxy-D-ribofuranose
• 英文别名: 1,2,3-Tri-O-acetyl-5-deoxy-D-lyxofuranose；[(2R,3S,4S)-4,5-diacetyloxy-2-methyloxolan-3-yl] acetate
• CAS: 202119-71-9
• 化学式: C₁₁H₁₆O₇
• 分子量: 260.244
• InChiKey: NXEJETQVUQAKTO-OCPQDWSXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  88.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tri-O-acetyl-5-deoxy-D-ribofuranose 在 氨 作用下， 以 甲醇 为溶剂， 生成 5-amino-3-(5-deoxy-β-D-ribofuranosyl)thiazolo<4,5-d>pyrimidine-2,7-dione
  参考文献：
  名称：

  噻唑并[4,5-d]嘧啶环系统中某些鸟苷类似物的合成及抗病毒活性。

  摘要：

  合成了嘌呤类似物5-氨基-3-β-D-呋喃核糖基噻唑并[4,5-d]嘧啶-2,7-二酮（1）的几种糖修饰的核苷衍生物。使用POCl3进行1的磷酸化反应，生成5'-单磷酸2，随后通过报道的方法转化为3'，5'-环磷酸3。通过用氯磺酰胺处理1的2，3-O-异亚丙基衍生物，然后进行酸脱保护，来合成5'-氨磺酰基衍生物4。化合物5-7、1的5'-脱氧，三-O-乙酰基和2'-脱氧衍生物分别通过5-氨基噻唑并[4,5-d]嘧啶-2,7的糖基化反应合成-二酮，1的糖苷配基，具有适当的糖部分，采用Vorbruggen程序。C2'-C3'的氧化裂解 在1中结合键，然后用硼氢化钠还原产生“ seco”类似物8。评价了核苷2-8在体内对Semliki森林病毒的抗病毒活性。化合物2、5和7的活性类似于1的活性。环状磷酸酯3在高剂量时有毒，而在低剂量时则弱。化合物4、6和8在该系统中没有活性。

  DOI：

  10.1021/jm00114a008
• 作为产物：
  描述：

  乙酸酐 、 (3S,4R,5R)-5-Methyl-tetrahydro-furan-2,3,4-triol 在 硫酸 、 溶剂黄146 作用下， 反应 20.0h， 生成 tri-O-acetyl-5-deoxy-D-ribofuranose
  参考文献：
  名称：

  Design, Synthesis, and Antiviral Activity of α-Nucleosides:  d- and l-Isomers of Lyxofuranosyl- and (5-Deoxylyxofuranosyl)benzimidazoles

  摘要：

  Several 2-substituted alpha-D- and alpha-L-lyxofuranosyl and 5-deoxylyxofuranosyl derivatives of 5,6-dichloro-2-(isopropylamino)-1- -(beta-L-ribofuranosyl)benzimidazole (1263W94) and 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB) were synthesized and evaluated for activity against two herpesviruses (HSV-1 and HCMV) and for their cytotoxicity against HFF and KB cells. Condensation of 1,2,3,5-tetra-O-acetyl-L-lyxofuranose (2a) with 2,5,6-trichlorobenzimidazole (1) yielded the or-nucleoside 3a. The 2-bromo derivative and 2-methylamino derivative were prepared by treatment of 3a with HBr followed by deprotection or from methylamine, respectively. Compound 3a was deprotected and the resultant nucleoside used to prepare the 2-cyclopropylamino and 2-isopropylamino derivatives. The 2-alkylthio nucleosides were prepared by condensing 2a with 5,6-dichlorobenzimidazole-2-thione followed by deprotection. Alkylation of this adduct gave the 2-methylthio and 2-benzylthio derivatives. Condensation of 5-deoxy-1,2,3-tri-O-acetyl-L-lyxofuranosyl, prepared from L-lyxose, with 1 or 2-bromo-5,6-dichlorobenzimidazole (15), followed by deprotection, gave the 2-chloro or 2-bromo-5'-deoxylyxofuranosyl derivative, respectively. The cyclopropylamino derivative was prepared from the 2-chloro derivative. All D-isomers were prepared in an analogous fashion from D-lyxose. Either compounds were inactive against HSV-1 or weak activity was poorly separated from cytoxicity. In contrast, the 2-halogen derivatives in both the alpha-lyxose and 5-deoxy-alpha-lyxose series were active against the Towne strain of HCMV. The 5-deoxy alpha-L analogues were the most active, IC50's = 0.2-0.4 mu M, plaque assay; IC90's = 0.2-2 mu M, yield reduction assay. All of the 2-isopropylamino or 2-cyclopropylamino derivatives were less active (IC50's = 60-100 mu M, plaque assay; IC90's = 17-100 mu M, yield reduction assay) and were not cytotoxic. The methylamino, thio, and methylthio derivatives were neither active nor cytotoxic. The benzylthio derivatives were weakly active, but this activity was poorly separated from cytotoxicity. The alpha-lyxose L-isomers were more active in a plaque assay against the AD169 strain of HCMV compared to the Towne strain, thereby providing additional evidence of antiviral specificity.

  DOI：

  10.1021/jm970545c

文献信息

• Benzimidazole derivatives for the treatment of viral infections
  申请人：The Regents of the University of Michigan

  公开号：US06413938B1

  公开（公告）日：2002-07-02

  According to a first aspect of the invention there is provided compounds of formula (I): wherein: R1 is hydroxy; O-acetyl; or a halo atom; R2 is hydroxy; O-acetyl; or a halo atom; R3 is hydrogen; a halo atom; azido; C2-6alkenyl; C2-6alkynyl; C6-14aryl C2-6alkenyl; C6-14arylC2-6alkynyl —NR8R9 (where R8 and R9 may be the same or different and are hydrogen, C1-8alkyl, cyanoC1-8alkyl, hydroxyC1-8alkyl, haloC1-8alkyl, C3-7cycloalkyl, C1-8alkylC3-7cycloalkyl, C2-6alkenyl, C3-7cycloalkylC1-8alkyl, C2-6alkynyl, C6-14aryl, C6-14arylC1-8alkyl, heterocycleC1-8alkyl, C1-8alkylcarbonyl, C6-14arylsulfonyl, C1-8alkysulfonyl, or R8R9 together with the N atom to which they are attached form a 3,4,5 or 6 membered heterocyclic ring); —OR10 (where R10 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl, C2-6alkenyl, C2-6alkynyl, C6-14aryl C2-6alkenyl or C6-14arylC2-6alkynyl); or —SR11 (where R11 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl).

  根据本发明的第一个方面，提供了以下式（I）的化合物：其中：R1是羟基；O-乙酰基；或卤原子；R2是羟基；O-乙酰基；或卤原子；R3是氢原子；卤原子；叠氮基；C2-6烯基；C2-6炔基；C6-14芳基C2-6烯基；C6-14芳基C2-6炔基-NR8R9（其中R8和R9可能相同也可能不同，为氢原子，C1-8烷基，氰基C1-8烷基，羟基C1-8烷基，卤基C1-8烷基，C3-7环烷基，C1-8烷基C3-7环烷基，C2-6烯基，C3-7环烷基C1-8烷基，C2-6炔基，C6-14芳基，C6-14芳基C1-8烷基，杂环C1-8烷基，C1-8烷基羰基，C6-14芳基磺酰基，C1-8烷基磺酰基，或R8R9与它们连接的N原子一起形成3,4,5或6个成员的杂环环）；-OR10（其中R10是氢原子，C1-8烷基，C6-14芳基，或C6-14芳基C1-8烷基，C2-6烯基，C2-6炔基，C6-14芳基C2-6烯基或C6-14芳基C2-6炔基）；或-SR11（其中R11是氢原子，C1-8烷基，C6-14芳基，或C6-14芳基C1-8烷基）。
• US6413938B1
  申请人：——

  公开号：US6413938B1

  公开（公告）日：2002-07-02